ReviewBioMed research international2014
The multiple roles of EG-VEGF/PROK1 in normal and pathological placental angiogenesis.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Molecular Changes on Maternal-Fetal Interface in Placental Abruption-A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Trial
- Maternal Docosahexaenoic Acid Status during Pregnancy and Its Impact on Infant Neurodevelopment.Nutrients · 2020Trial
- Trial
- Genome-Wide Association Study of Body Measurement Traits at Birth in Cattle.Animals : an open access journal from MDPI · 2026Article
- Progesterone receptor, prokineticin 1, LncRNA-H19, and miR-210 in molecular regulation of recurrent implantation failure.Scientific reports · 2026Article
- Inhibition of Fibroblast Activation Protein-α Ameliorates Intervertebral Disc Degeneration via Reduced Vascular Invasion in Cartilage Endplate.Cell proliferation · 2026Article
- Diagnostic and prognostic role of maternal serum prokineticin-1 in preeclampsia and adverse pregnancy outcomes.Journal of the Turkish German Gynecological Association · 2026Article
- Diagnostic value of sFlt-1/PlGF-1 ratio and plasma PROK1 for adverse pregnancy outcomes in women with hypertensive disease of pregnancy.The Kaohsiung journal of medical sciences · 2024Article
- Genetic Polymorphisms of Prokineticins and Prokineticin Receptors Associated with Human Disease.Life (Basel, Switzerland) · 2024Review
- Molecular regulators of defective placental and cardiovascular development in fetal growth restriction.Clinical science (London, England : 1979) · 2024Review
- Associations between synthetic phenols, phthalates, and placental growth/function: a longitudinal cohort with exposure assessment in early pregnancy.Human reproduction open · 2024Article
- Novel Insights into Prokineticin 1 Role in Pregnancy-related Diseases.International journal of medical sciences · 2024Review
- EG-VEGF maternal levels predict spontaneous preterm birth in the second and third trimesters in pregnant women with risk factors for placenta-mediated complications.Scientific reports · 2023Article
- Therapeutic Potential of Targeting Prokineticin Receptors in Diseases.Pharmacological reviews · 2023Review
- Effects of Prokineticins on Cerebral Cell Function and Blood-Brain Barrier Permeability.International journal of molecular sciences · 2023Article
- Prokineticin 1 is a novel factor regulating porcine corpus luteum function.Scientific reports · 2023Article
- Proteotranscriptomic analyses reveal distinct interferon-beta signaling pathways and therapeutic targets in choroidal neovascularization.Frontiers in immunology · 2023Article
- Association of Single Nucleotide Polymorphisms from Angiogenesis-Related Genes,Current issues in molecular biology · 2022Article
- Prediction of pre-eclampsia complicated by fetal growth restriction and its perinatal outcome based on an artificial neural network model.Frontiers in physiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Placentation is associated with several steps of vascular adaptations throughout pregnancy. These vascular changes occur both on the maternal and fetal sides, consisting of maternal uterine spiral arteries remodeling and placental vasculogenesis and angiogenesis, respectively. Placental angiogenesis is a pivotal process for efficient fetomaternal exchanges and placental development. This process is finely controlled throughout pregnancy, and it involves ubiquitous and pregnancy-specific angiogenic factors. In the last decade, endocrine gland derived vascular endothelial growth factor (EG-VEGF), also called prokineticin 1 (PROK1), has emerged as specific placental angiogenic factor that controls many aspects of normal and pathological placental angiogenesis such as recurrent pregnancy loss (RPL), gestational trophoblastic diseases (GTD), fetal growth restriction (FGR), and preeclampsia (PE). This review recapitulates EG-VEGF mediated-angiogenesis within the placenta and at the fetomaternal interface and proposes that its deregulation might contribute to the pathogenesis of several placental diseases including FGR and PE. More importantly this paper argues for EG-VEGF clinical relevance as a potential biomarker of the onset of pregnancy pathologies and discusses its potential usefulness for future therapeutic directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.